Evidence map›Paper›PMID 37352344›Full record

ArticleScience advances2023

Sequential apoptotic and multiplexed proteomic evaluation of single cancer cells.

Emmalyn Lecky, Atreyi Mukherji, Rebecca German, Gabriella Antonellis, Jia-Ren Lin, Michael Yorsz, Kelley E McQueeney, Jeremy Ryan, Kimmie Ng, Ewa Sicinska and 3 more

Open access · goldAbstract read
In one paragraph

Article in Science advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Emmalyn LeckyDana Farber Cancer Institute, Boston MA 02215, USA.ORCID 0000-0001-6005-1895
Atreyi MukherjiDana Farber Cancer Institute, Boston MA 02215, USA.ORCID 0000-0003-1562-0483
Rebecca GermanDana Farber Cancer Institute, Boston MA 02215, USA.ORCID 0009-0001-2545-9550
Gabriella AntonellisDana Farber Cancer Institute, Boston MA 02215, USA.
Jia-Ren LinHarvard Medical School, Boston MA 02215, USA.ORCID 0000-0003-4702-7705
Michael YorszDana Farber Cancer Institute, Boston MA 02215, USA.
Kelley E McQueeneyDana Farber Cancer Institute, Boston MA 02215, USA.ORCID 0000-0002-2596-9016
Jeremy RyanDana Farber Cancer Institute, Boston MA 02215, USA.ORCID 0000-0002-3327-1283
Kimmie NgDana Farber Cancer Institute, Boston MA 02215, USA.ORCID 0000-0003-0631-1494
Ewa SicinskaDana Farber Cancer Institute, Boston MA 02215, USA.
Peter K SorgerHarvard Medical School, Boston MA 02215, USA.ORCID 0000-0002-3364-1838
Anthony LetaiDana Farber Cancer Institute, Boston MA 02215, USA.ORCID 0000-0002-1993-9013
Patrick D BholaDana Farber Cancer Institute, Boston MA 02215, USA.ORCID 0000-0002-2438-4526
Dana-Farber Cancer Institute · USHarvard University · US

Funding

Pre-cancer atlases of cutaneous and hematologic origin (PATCH Center)U2CCA233262 · NCI · HARVARD MEDICAL SCHOOL · PI SANTAGATA, SANDRO, SORGER, PETER KARL · 2018 to 2023
$8.7M
Reading mitochondrial apoptotic signaling to identify active cancer therapeuticsR35CA242427 · NCI · DANA-FARBER CANCER INST · PI LETAI, ANTHONY G · 2019 to 2025
$7.0M
Novel randomized controlled trials of vitamin D supplementation in patients with colorectal cancer: Impact on survival and biologyR01CA205406 · NCI · DANA-FARBER CANCER INST · PI Kimmie Ng · 2017 to 2026
$4.9M
Advancing technologies for the collection and analysis of high dimensional immunoprofiles and tumor imagesR50CA274277 · NCI · HARVARD MEDICAL SCHOOL · PI Jia-Ren Lin · 2022 to 2026
$879k
NCI NIH HHS R01 CA205406NCI NIH HHS R35 CA242427NCI NIH HHS R50 CA274277NCI NIH HHS U2C CA233262
6 · The paper itself

Abstract

A potential cause of cancer relapse is pretreatment chemoresistant subpopulations. Identifying targetable features of subpopulations that are poorly primed for therapy-induced cell death may improve cancer therapy. Here, we develop and validate real-time BH3 profiling, a live and functional single-cell measurement of pretreatment apoptotic sensitivity that occurs upstream of apoptotic protease activation. On the same single cells, we perform cyclic immunofluorescence, which enables multiplexed immunofluorescence of more than 30 proteins on the same cell. Using cultured cells and rapid ex vivo cultures of colon cancer patient-derived xenograft (PDX) models, we identify Bak as a univariate correlate of apoptotic priming, find that poorly primed subpopulations can correspond to specific stages of the cell cycle, and, in some PDX models, identify increased expression of Bcl-XL, Mcl-1, or Her2 in subpopulations that are poorly primed for apoptosis. Last, we generate and validate mathematical models of single-cell priming that describe how targetable proteins contribute to apoptotic priming.

Indexed as

ApoptosisNeoplasmsCell Line, TumorHumansProteomicsSingle-Cell Analysis

Identifiers

PMID37352344
PMCPMC10289660
OpenAlexW4381803283

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.